Show simple item record

dc.contributor.authorTomini, F
dc.contributor.authorPrinzen, F
dc.contributor.authorvan Asselt, ADI
dc.date.accessioned2019-03-07T12:47:30Z
dc.date.available2015-11-25
dc.date.available2019-03-07T12:47:30Z
dc.date.issued2016-01-04
dc.identifier.citationTomini, F., et al. (2016). "A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure." The European Journal of Health Economics 17(9): 1159-1172.en_US
dc.identifier.issn1618-7598
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/55911
dc.description.abstractObjectives Cardiac resynchronization therapy with a biventricular pacemaker (CRT-P) is an effective treatment for dyssynchronous heart failure (DHF). Adding an implantable cardioverter defibrillator (CRT-D) may further reduce the risk of sudden cardiac death (SCD). However, if the majority of patients do not require shock therapy, the cost-effectiveness ratio of CRT-D compared to CRT-P may be high. The objective of this study was to systematically review decision models evaluating the cost-effectiveness of CRT-D for patients with DHF, compare the structure and inputs of these models and identify the main factors influencing the ICERs for CRT-D. Methods A comprehensive search strategy of Medline (Ovid), Embase (Ovid) and EconLit identified eight cost-effectiveness models evaluating CRT-D against optimal pharmacological therapy (OPT) and/or CRT-P. Results The selected economic studies differed in terms of model structure, treatment path, time horizons, and sources of efficacy data. CRT-D was found cost-effective when compared to OPT but its cost-effectiveness became questionable when compared to CRT-P. Conclusions Cost-effectiveness of CRT-D may increase depending on improvement of all-cause mortality rates and HF mortality rates in patients who receive CRT-D, costs of the device, and battery life. In particular, future studies need to investigate longer-term mortality rates and identify CRT-P patients that will gain the most, in terms of life expectancy, from being treated with a CRT-D.en_US
dc.description.sponsorshipThis work was supported by the Center for Translational Molecular Medicine and The Netherlands Heart Foundation under the ‘Biomarkers to predict cardiac failure, arrhythmias and success of treatment’ (COHFAR) projecten_US
dc.format.extent1159 - 1172
dc.language.isoenen_US
dc.publisherSpringerLinken_US
dc.relation.ispartofEUROPEAN JOURNAL OF HEALTH ECONOMICS
dc.rightsCreative Commons Attribution
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subjectReviewen_US
dc.subjectCost-effectivenessen_US
dc.subjectCardiac resynchronization therapyen_US
dc.subjectCardiac pacingen_US
dc.subjectImplantable cardioverter-defibrillatoren_US
dc.subjectMarkov chainsen_US
dc.subjectModelsen_US
dc.subjectEconomicen_US
dc.subjectHeart failureen_US
dc.subjectSudden cardiac deathen_US
dc.titleA review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failureen_US
dc.typeArticleen_US
dc.rights.holderThe Author(s) 2016
dc.identifier.doi10.1007/s10198-015-0752-3
pubs.author-urlhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000392436000009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6aen_US
pubs.issue9en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume17en_US
dcterms.dateAccepted2015-11-25
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution
Except where otherwise noted, this item's license is described as Creative Commons Attribution